Trial reportBMC complementary medicine and therapies2026
Clinical evaluation of the efficacy and safety of nasturtium herb and horseradish root versus placebo in the continuous prophylaxis of recurrent uncomplicated cystitis: a double-blind randomised clinical trial.
Trial report in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThis study aimed to demonstrate the efficacy and safety of a herbal combination drug of nasturtium herb and horseradish root in the continuous prophylaxis of recurring uncomplicated cystitis.
methodsThe clinical trial was conducted as a phase III, two-armed, placebo-controlled, randomised, double-blind, prospective, and multi-center study, which followed a parallel-group design in Germany. Data were collected in a multicenter setup in Germany. Patients of either sex aged ≥ 18 years with recurring uncomplicated cystitis were considered for the study. Interventions were Nasturtium herb and horseradish root prophylaxis versus placebo. The primary outcome measure was the rate of first recurrent urinary tract infection (rUTI) observed during six months of recurrence prophylaxis in the herbal and the placebo group from day 0 to day 180. Additional efficacy outcome measures included: recurrence rates at scheduled visits during the course of recurrence prophylaxis; recurrence rates during three- and six-month follow-up and Investigator’s assessment of efficacy at completion of recurrence prophylaxis. Safety evaluation included type, frequency, and severity of reported adverse events.
resultsA total of 224 patients were enrolled, of which 217 women were included in the full analysis set. Patients were randomised to treatment with either nasturtium herb and horseradish root (N = 110) or placebo (N = 107). The cumulative recurrence rate increased for the placebo group to approximately 40% by day 90 and 48% by day 180, while the nasturtium herb and horseradish root group had lower rates of 26% and 36%, respectively. The overall risk of rUTI was reduced by 36% (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.42–0.97, p = 0.0327) in the treatment group. This effect remained consistent (although statistically insignificant) during the follow-up period up to 360 days. There were no significant differences between groups, for any of the reported adverse effects.
conclusionThe results of this study indicate that nasturtium herb and horseradish root may be an effective, safe prophylactic treatment for female patients suffering from rUTIs.
trial registrationThis trial was registered with EudraCT under the number: EudraCT 2013-004653-25. The study was approved on 2nd of May 2014 and the first participant was enrolled on 9th of May 2014.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.